CN113166210A - 用于选择性抑制痤疮丙酸杆菌生长的抗微生物组合物 - Google Patents
用于选择性抑制痤疮丙酸杆菌生长的抗微生物组合物 Download PDFInfo
- Publication number
- CN113166210A CN113166210A CN201980034215.6A CN201980034215A CN113166210A CN 113166210 A CN113166210 A CN 113166210A CN 201980034215 A CN201980034215 A CN 201980034215A CN 113166210 A CN113166210 A CN 113166210A
- Authority
- CN
- China
- Prior art keywords
- composition
- propionibacterium acnes
- scu
- endolysin
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 65
- 241000186427 Cutibacterium acnes Species 0.000 title claims abstract description 47
- 229940055019 propionibacterium acne Drugs 0.000 title claims abstract description 38
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 9
- 230000000845 anti-microbial effect Effects 0.000 title claims description 13
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 28
- 206010000496 acne Diseases 0.000 claims abstract description 28
- 238000000034 method Methods 0.000 claims abstract description 23
- 241001515965 unidentified phage Species 0.000 claims abstract description 11
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 5
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 5
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 27
- 241001147736 Staphylococcus capitis Species 0.000 claims description 19
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 18
- KDXKERNSBIXSRK-UHFFFAOYSA-N lysine Chemical compound NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 11
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 8
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 8
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 241000588724 Escherichia coli Species 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 6
- 239000008188 pellet Substances 0.000 claims description 5
- 241000186429 Propionibacterium Species 0.000 claims description 4
- 239000004599 antimicrobial Substances 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 239000006210 lotion Substances 0.000 claims description 4
- 108020004705 Codon Proteins 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims description 2
- 230000004927 fusion Effects 0.000 claims description 2
- 230000002934 lysing effect Effects 0.000 claims description 2
- 239000008363 phosphate buffer Substances 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 abstract description 5
- 244000005714 skin microbiome Species 0.000 abstract description 3
- 230000037311 normal skin Effects 0.000 abstract description 2
- 241001619326 Cephalosporium Species 0.000 abstract 1
- 241000894007 species Species 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 27
- -1 igin Species 0.000 description 24
- 239000000194 fatty acid Substances 0.000 description 18
- 239000000344 soap Substances 0.000 description 17
- 235000014113 dietary fatty acids Nutrition 0.000 description 14
- 229930195729 fatty acid Natural products 0.000 description 14
- 239000004094 surface-active agent Substances 0.000 description 14
- 150000004665 fatty acids Chemical class 0.000 description 12
- 241000191963 Staphylococcus epidermidis Species 0.000 description 10
- 244000005700 microbiome Species 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 241000191967 Staphylococcus aureus Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000003974 emollient agent Substances 0.000 description 8
- 230000000475 sunscreen effect Effects 0.000 description 7
- 239000000516 sunscreening agent Substances 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000003906 humectant Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000006150 trypticase soy agar Substances 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical class C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 4
- 108010013639 Peptidoglycan Proteins 0.000 description 4
- 241000202921 Ureaplasma urealyticum Species 0.000 description 4
- 108010046334 Urease Proteins 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000002736 nonionic surfactant Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000003760 tallow Substances 0.000 description 4
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 4
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical class NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 241000202898 Ureaplasma Species 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 150000008051 alkyl sulfates Chemical class 0.000 description 3
- 239000003945 anionic surfactant Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 150000002191 fatty alcohols Chemical class 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 210000002374 sebum Anatomy 0.000 description 3
- 229920002545 silicone oil Polymers 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- 208000020154 Acnes Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 235000017060 Arachis glabrata Nutrition 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- 235000010777 Arachis hypogaea Nutrition 0.000 description 2
- 235000018262 Arachis monticola Nutrition 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N Behenic acid Natural products CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- 244000060011 Cocos nucifera Species 0.000 description 2
- 235000013162 Cocos nucifera Nutrition 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 239000004606 Fillers/Extenders Substances 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 108090000604 Hydrolases Proteins 0.000 description 2
- 102000004157 Hydrolases Human genes 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 2
- 235000019774 Rice Bran oil Nutrition 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 150000001277 beta hydroxy acids Chemical class 0.000 description 2
- UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Chemical compound CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 description 2
- 238000010876 biochemical test Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- UVCJGUGAGLDPAA-UHFFFAOYSA-N ensulizole Chemical compound N1C2=CC(S(=O)(=O)O)=CC=C2N=C1C1=CC=CC=C1 UVCJGUGAGLDPAA-UHFFFAOYSA-N 0.000 description 2
- 229960000655 ensulizole Drugs 0.000 description 2
- 239000010696 ester oil Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N ethyl stearic acid Natural products CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N iso-octadecanoic acid Natural products CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N methyl undecanoic acid Natural products CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- AOHAPDDBNAPPIN-UHFFFAOYSA-N myristicinic acid Natural products COC1=CC(C(O)=O)=CC2=C1OCO2 AOHAPDDBNAPPIN-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N n-hexadecanoic acid Natural products CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229920001206 natural gum Polymers 0.000 description 2
- FBUKVWPVBMHYJY-UHFFFAOYSA-N noncarboxylic acid Natural products CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 2
- 229960001679 octinoxate Drugs 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229960001173 oxybenzone Drugs 0.000 description 2
- 235000020232 peanut Nutrition 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000008165 rice bran oil Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 210000001732 sebaceous gland Anatomy 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 150000003871 sulfonates Chemical class 0.000 description 2
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 235000007586 terpenes Nutrition 0.000 description 2
- 150000003751 zinc Chemical class 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- OIQXFRANQVWXJF-QBFSEMIESA-N (2z)-2-benzylidene-4,7,7-trimethylbicyclo[2.2.1]heptan-3-one Chemical class CC1(C)C2CCC1(C)C(=O)\C2=C/C1=CC=CC=C1 OIQXFRANQVWXJF-QBFSEMIESA-N 0.000 description 1
- ZHYZQXUYZJNEHD-CLFYSBASSA-N (2z)-3,7-dimethylocta-2,6-dienoic acid Chemical compound CC(C)=CCC\C(C)=C/C(O)=O ZHYZQXUYZJNEHD-CLFYSBASSA-N 0.000 description 1
- BJDAUCLANVMIOB-UHFFFAOYSA-N (3-decanoyloxy-2,2-dimethylpropyl) decanoate Chemical compound CCCCCCCCCC(=O)OCC(C)(C)COC(=O)CCCCCCCCC BJDAUCLANVMIOB-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- ZWVMLYRJXORSEP-UHFFFAOYSA-N 1,2,6-Hexanetriol Chemical compound OCCCCC(O)CO ZWVMLYRJXORSEP-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- JQJSFAJISYZPER-UHFFFAOYSA-N 1-(4-chlorophenyl)-3-(2,3-dihydro-1h-inden-5-ylsulfonyl)urea Chemical compound C1=CC(Cl)=CC=C1NC(=O)NS(=O)(=O)C1=CC=C(CCC2)C2=C1 JQJSFAJISYZPER-UHFFFAOYSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- CMTPCYKEUFDVAU-UHFFFAOYSA-N 2,5-dimethylthiophene-3-sulfonyl chloride Chemical compound CC1=CC(S(Cl)(=O)=O)=C(C)S1 CMTPCYKEUFDVAU-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- QTDIEDOANJISNP-UHFFFAOYSA-N 2-dodecoxyethyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOCCOS(O)(=O)=O QTDIEDOANJISNP-UHFFFAOYSA-N 0.000 description 1
- CLAHOZSYMRNIPY-UHFFFAOYSA-N 2-hydroxyethylurea Chemical compound NC(=O)NCCO CLAHOZSYMRNIPY-UHFFFAOYSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 description 1
- NZXZINXFUSKTPH-UHFFFAOYSA-N 4-[4-(4-butylcyclohexyl)cyclohexyl]-1,2-difluorobenzene Chemical compound C1CC(CCCC)CCC1C1CCC(C=2C=C(F)C(F)=CC=2)CC1 NZXZINXFUSKTPH-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 241001136167 Anaerotignum propionicum Species 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
- 235000005881 Calendula officinalis Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- FMRHJJZUHUTGKE-UHFFFAOYSA-N Ethylhexyl salicylate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1O FMRHJJZUHUTGKE-UHFFFAOYSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- GWFGDXZQZYMSMJ-UHFFFAOYSA-N Octadecansaeure-heptadecylester Natural products CCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC GWFGDXZQZYMSMJ-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 241000316848 Rhodococcus <scale insect> Species 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- 208000015390 Sebaceous gland disease Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 241001279373 Staphylococcus capitis subsp. urealyticus Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical class OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 240000000785 Tagetes erecta Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 239000004164 Wax ester Substances 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 125000005227 alkyl sulfonate group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- VYBREYKSZAROCT-UHFFFAOYSA-N alpha-myrcene Natural products CC(=C)CCCC(=C)C=C VYBREYKSZAROCT-UHFFFAOYSA-N 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940053195 antiepileptics hydantoin derivative Drugs 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- 229940094974 arachidyl behenate Drugs 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000010480 babassu oil Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- FQUNFJULCYSSOP-UHFFFAOYSA-N bisoctrizole Chemical compound N1=C2C=CC=CC2=NN1C1=CC(C(C)(C)CC(C)(C)C)=CC(CC=2C(=C(C=C(C=2)C(C)(C)CC(C)(C)C)N2N=C3C=CC=CC3=N2)O)=C1O FQUNFJULCYSSOP-UHFFFAOYSA-N 0.000 description 1
- 229960003055 bisoctrizole Drugs 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 125000000853 cresyl group Chemical group C1(=CC=C(C=C1)C)* 0.000 description 1
- 239000006814 cy-agar Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229930008394 dihydromyrcenol Natural products 0.000 description 1
- XSNQECSCDATQEL-UHFFFAOYSA-N dihydromyrcenol Chemical compound C=CC(C)CCCC(C)(C)O XSNQECSCDATQEL-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229940068171 ethyl hexyl salicylate Drugs 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 244000000059 gram-positive pathogen Species 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- QAKXLTNAJLFSQC-UHFFFAOYSA-N hexadecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC QAKXLTNAJLFSQC-UHFFFAOYSA-N 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 150000001469 hydantoins Chemical class 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940031575 hydroxyethyl urea Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 229940100554 isononyl isononanoate Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- NKBWPOSQERPBFI-UHFFFAOYSA-N octadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCCCC NKBWPOSQERPBFI-UHFFFAOYSA-N 0.000 description 1
- FMJSMJQBSVNSBF-UHFFFAOYSA-N octocrylene Chemical group C=1C=CC=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 FMJSMJQBSVNSBF-UHFFFAOYSA-N 0.000 description 1
- 229960000601 octocrylene Drugs 0.000 description 1
- 150000002888 oleic acid derivatives Chemical class 0.000 description 1
- BARWIPMJPCRCTP-UHFFFAOYSA-N oleic acid oleyl ester Natural products CCCCCCCCC=CCCCCCCCCOC(=O)CCCCCCCC=CCCCCCCCC BARWIPMJPCRCTP-UHFFFAOYSA-N 0.000 description 1
- BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000024241 parasitism Effects 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000012177 spermaceti Substances 0.000 description 1
- 229940084106 spermaceti Drugs 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- ZHYZQXUYZJNEHD-UHFFFAOYSA-N trans-geranic acid Natural products CC(C)=CCCC(C)=CC(O)=O ZHYZQXUYZJNEHD-UHFFFAOYSA-N 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- ZQTYRTSKQFQYPQ-UHFFFAOYSA-N trisiloxane Chemical compound [SiH3]O[SiH2]O[SiH3] ZQTYRTSKQFQYPQ-UHFFFAOYSA-N 0.000 description 1
- 230000003604 ureolytic effect Effects 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 235000019386 wax ester Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229940043810 zinc pyrithione Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明涉及通过选择性抑制痤疮丙酸杆菌(P.acnes)细菌来预防或治疗痤疮的方法和组合物。该方法包括用作为正常皮肤菌群的次要贡献者存在的另一种细菌头状葡萄球菌解脲亚种(Staphylococcus capitis ureolyticus,SCU)的分离物处理皮肤。当痤疮丙酸杆菌噬菌体来源的内溶素和编码它们的核酸分子被包含在内时,则功效得到进一步增强。
Description
技术领域
本发明涉及通过选择性抑制痤疮丙酸杆菌(P.acnes)细菌来预防或治疗痤疮的方法和组合物。该方法包括用作为正常皮肤菌群的次要贡献者存在的另一种细菌的分离物处理皮肤。
背景技术
痤疮,又称寻常痤疮,是常见的皮肤病况,其几乎在所有青少年和成年人生命中的某些时间影响他们。它具有复杂的病因,涉及异常的角质化、过多的皮脂产生、雄激素功能、细菌生长和免疫超敏反应。尽管上述过程中的一个或多个与痤疮相关,但尚未完全了解触发导致痤疮病变形成的因素的过程和导致痤疮病变形成的事件的确切顺序。其他与痤疮有关的因素是自由基的存在以及随后的导致细胞损伤的氧化应激。据观察,痤疮通常发生在皮脂腺丰富的区域,如面部、颈部和背部。
细菌痤疮丙酸杆菌(Propionibacterium acnes或P.acnes)也与痤疮的出现有关。它是存在于人面部皮肤表面上的重要和优势细菌之一。痤疮丙酸杆菌是耐氧厌氧性、生长缓慢的杆状革兰氏阳性细菌。它位于皮脂腺中,并且它构成皮肤共生微生物区系的重要部分。痤疮丙酸杆菌使用皮脂和来自周围皮肤组织的副产物作为能量和营养素的来源。这导致某些脂肪酸释放,脂肪酸释放可刺激毛囊壁并引起炎症,导致痤疮或寻常痤疮。寻常痤疮是慢性炎症性皮脂腺病症。它几乎在所有青少年生命中的某些时刻影响他们,其中15-20%罹患中度至重度形式的痤疮。
已经以许多方式治疗痤疮。大多数治疗花费几周到几个月后看到明显的变化。具有抗微生物作用的过氧化苯甲酰已被用于轻度粉刺病例。在非常严重的痤疮病例中,已使用抗生素如四环素、红霉素和克林霉素。据信抗生素通过几种机制起作用,最重要的是毛囊内和周围的细菌数量减少。还认为它们减少皮脂中白细胞产生的刺激性化学物质,从而减少炎症反应。然而,抗生素和其他种类的常规抗微生物治疗的缺点是它们是广谱的,并且有助于杀死或抑制皮肤上的大多数细菌。
如上所总结的,大多数治疗都涉及使用合成化学物质。许多人不喜欢使用合成化学物质,因为据信它们对人体有害。一些人相信合成化学物质引起副作用。因此,越来越多的人喜欢使用“天然”的材料,例如基于草药来源的活性物质。此外,近来,基于微生物或生物技术来源的活性物质也被认为比迄今所使用的纯合成方法更“天然”。
人体的最大器官皮肤被各种各样的微生物定殖。大多数微生物被认为是有益的或者是机会性的潜在病原体。DNA测序和计算生物学的近期进展正在帮助我们以更高分辨率识别和了解这些微生物对我们皮肤的有益作用。
皮肤微生物与人宿主之间的相互作用可分为三类:1.偏利共生(一方受益,且对另一方没有伤害),2.互利共生(双方都有益处),3.寄生(一种生物体受益,且另一种受到伤害)。通常与疾病无关的微生物主要被称为共生菌(commensals)。越来越多的证据表明,皮肤上的共生生物体帮助免疫系统抵抗病原体并维持微生物群(microbiome)的稳态。一个实例是表皮葡萄球菌(Staphylococcus epidermidis,一种革兰氏阳性凝固酶阴性葡萄球菌),其在痤疮抑制中起重要作用。表皮葡萄球菌介导甘油的发酵,这抑制痤疮丙酸杆菌的过度生长,导致痤疮抑制。因此,使用杀死或抑制皮肤上所有微生物的广谱抗生素作用的方法在医疗保健从业人员中越来越少被接受。选择性杀死或抑制皮肤上的微生物的方法越来越受到医疗保健从业者的青睐。此外,在治疗痤疮丙酸杆菌的抗生素耐药性菌株中使用抗生素是无效的。
因此,需要找到以选择性方式治疗诸如痤疮的问题的新方法。因此,本发明人开始致力于提供“天然”解决方案来解决痤疮问题。他们采用了测试杀死痤疮丙酸杆菌或选择性抑制痤疮丙酸杆菌(排除其他生物体如表皮葡萄球菌、大肠杆菌(E.coli)和金黄色葡萄球菌(S.aureus))生长的新活性物质并用其进行实验。他们最终找到了头状葡萄球菌解脲亚种(SCU,皮肤菌群的次要贡献者)的分离物(细胞外因子),发现其选择性抑制痤疮丙酸杆菌的生长。
名称为“Treatments for resistant acne”的US2016346294(VyomeBiosciences)一般而言总体涉及用于治疗细菌感染的新的分子、组合物和制剂,并且更具体地涉及关于抗生素耐药性病原体的细菌感染。其中举例说明的是头状葡萄球菌(未特别提及亚种),其被认为是病原体,不是抗微生物剂。
因此,本发明的目的是提供对痤疮丙酸杆菌的选择性杀死或抑制以治疗痤疮。
本发明的另一目的是提供通过更天然或基于天然的活性物质治疗痤疮的解决方案。
发明内容
根据本发明的第一方面,提供了用于选择性抑制痤疮丙酸杆菌细菌生长的抗微生物组合物,其包含:
(i)头状葡萄球菌解脲亚种(Staphylococcus capitis ureolyticus,SCU)分离物;和
(ii)局部可接受的载体。
根据本发明的另一方面,提供了控制或根除来自皮肤的痤疮丙酸杆菌的方法,其包括将第一方面的组合物施用于所需皮肤表面上的步骤。
具体实施方式
通过阅读以下详细描述和所附的权利要求书,这些和其他方面、特征和优点对于本领域普通技术人员会是清楚的。为避免疑义,本发明的一个方面的任何特征均可用于本发明的任何其他方面。词语“包括(comprising)”旨在表示“包括(including)”,但不一定是“由……组成(consisting of)”或“由……构成(composed of)”。换言之,列出的步骤或选项不必是穷尽的。应注意的是,以下描述中给出的实施例旨在阐明本发明,并非旨在将本发明限制于那些实施例本身。类似地,除非另有说明,所有百分比均为重量/重量百分比。
除了在操作例和比较例中或者另外明确指出以外,本说明书中表示材料量或反应条件、材料的物理性质和/或用途的所有数字均应理解为由词语“约”修饰。除非另外说明,以“x至y”的形式表示的数值范围应理解为包括x和y。当对于具体特征,以“x至y”的形式描述多个优选范围时,应理解组合不同端点的所有范围均也被涵盖。
根据本发明的组合物可以是用于清洁或消毒局部区域(例如哺乳动物,尤其是人的皮肤和/或毛发)的免洗型或洗去型形式。这样的组合物包括还用于改善外观、清洁、气味控制或总体美观的施用于人体的任何产品。本发明的组合物可为液体、洗剂、乳膏、泡沫或凝胶或化妆水的形式,或用工具施用或经由面膜、垫或贴片施用。如本文所用的“皮肤”是指包括面部和身体上的皮肤(例如,颈部、胸部、背部、手臂、腋下、手、腿、臀部和头皮)。它对于治疗面部上或痤疮形成的任何其他身体部位上的痤疮特别有用。
本发明涉及用于选择性抑制痤疮丙酸杆菌细菌生长的抗微生物组合物,其包含:(i)头状葡萄球菌解脲亚种(SCU)分离物;和(ii)局部可接受的载体。
头状葡萄球菌是位于人面部上的正常菌群的次要贡献者。头状葡萄球菌是革兰氏阳性凝固酶阴性葡萄球菌。在本发明中,发明人发现头状葡萄球菌解脲亚种(头状葡萄球菌的亚种)分泌抑制痤疮丙酸杆菌和颗粒丙酸杆菌(P.granulosum)而非表皮葡萄球菌、大肠杆菌和金黄色葡萄球菌生长的蛋白质因子。因此,设想丙酸杆菌的这种选择性/靶向减少可能是控制寻常痤疮内的痤疮丙酸杆菌种群,同时保持面部皮肤微生物群的平衡的有效益生元/益生菌方法。
本发明中使用的细菌菌株和生长条件如下:
头状葡萄球菌临床分离物菌株(SCU,从志愿者的面部分离)。使用胰蛋白酶大豆培养基和胰蛋白酶大豆琼脂在37℃下的需氧条件下恢复菌株。
通过16s rDNA测序证实头状葡萄球菌的临床分离物。
用于测序的引物是
使用以下程序将临床分离物SCU鉴定为头状葡萄球菌解脲亚种。
进行生化测试以表征头状葡萄球菌的菌株。SCU对两个生化测试(脲酶活性和麦芽糖发酵测试)均呈阳性。
脲酶测试定义可以裂解存在于培养基中的脲并形成氨和二氧化碳的生物体的脲酶活性。随后,氨与二氧化碳和水结合,形成使培养基变成碱性的碳酸铵。由于碱性pH,培养基从黄色(原始颜色)变成粉红色。
麦芽糖发酵测试定义通过微生物进行的碳水化合物(糖)麦芽糖发酵。麦芽糖发酵导致作为副产物的酸产生,其使培养基变为酸性。由于酸性pH,培养基从红色(原始颜色)变为黄色。根据Kloos分类,头状葡萄球菌解脲亚种可以通过它们的阳性脲酶活性和麦芽糖发酵与头状葡萄球菌的其他亚种区分。
因此,为本发明制备的SCU是头状葡萄球菌解脲亚种的临床分离物。
根据本发明的SCU分离物优选使用包括以下步骤的方法制备:(i)在35至37℃的温度下在液体培养基中摇动SCU;(ii)分离不含细胞的上清液;(iii)通过用硫酸铵沉淀来浓缩所述上清液;和(iv)用磷酸盐缓冲液和甘油重悬步骤(iii)的沉淀物以制备所需SCU分离物。
优选的方法如以下给出。通过在35至37℃下摇动液体培养基中的SCU过夜而制备SCU的上清液。通过将该过夜培养物在约10000g下离心约10-20分钟,优选约15分钟来制备不含细胞的上清液。在约4℃持续搅拌过夜下,向不含细胞的上清液中加入约75%硫酸铵。次日,将经硫酸铵处理的上清液在约10000g下离心约30分钟,并将获得的沉淀重悬于含约10%甘油的1X PBS(pH 7.0)中。进行过夜透析以对PBS缓冲液和10%甘油除去硫酸铵。次日,将透析的级分等分并储存在-80℃下直至进一步使用。
根据本发明的头状葡萄球菌解脲亚种(SCU)分离物是指SCU培养物的上清液。因此,在整个说明书和权利要求书中,术语“头状葡萄球菌解脲亚种(SCU)分离物”和术语“SCU培养物上清液”可互换使用。在前两段中已经描述了一种制备SCU培养物的这种上清液的方法。上文描述的方法使术语“头状葡萄球菌解脲亚种(SCU)分离物”的含义非常清楚。根据本发明的SCU分离物并不意味着如下文献中所公开的仅从皮肤分离的SCU:Tammy LBannerman等人,“Staphylococcus capitis subsp.ureolyticus subsp.nov.from HumanSkin”,International Journal of Systematic Bacteriology,1991年1月1日,第144-147页,XP055493126。
根据本发明的组合物可另外包含痤疮丙酸杆菌噬菌体来源的内溶素和编码它们的核酸分子。
除了根据本发明第一方面的提供选择性抗微生物功效的SCU分离物之外,本发明人还寻求对该技术的改进。为此目的,他们考察了各种其他方法,并实现了噬菌体和噬菌体来源的酶的应用。一组噬菌体来源的酶是称为内溶素的肽聚糖(PG)水解酶。内溶素是由双链DNA噬菌体编码的新的胞壁质(muralytic)水解酶,其降解细菌细胞壁的PG层,从而使子代噬菌体在感染周期的后期逸出。纯化的内溶素在外部暴露于PG时可以导致“从外部裂解”。基于它们的抗微生物性质(外部添加时具有非凡的底物特异性和高活性),来自感染革兰氏阳性病原体的噬菌体的内溶素是本发明人改善本发明第一方面所表现出的作用的动机和假设。
不希望受到理论的束缚,本发明人相信痤疮丙酸杆菌噬菌体来源的内溶素的应用提供对此有前途的途径,因为尚未记录对内溶素的抗微生物耐药性。他们已经使用大肠杆菌基的异源表达系统成功表达并纯化痤疮丙酸杆菌噬菌体内溶素的重组形式,并已证明其选择性体外裂解痤疮丙酸杆菌的能力。内溶素不靶向于人皮肤上发现的任何常规细菌菌群,即金黄色葡萄球菌、表皮葡萄球菌或大肠杆菌。
因此,有用的是所包含的内溶素是痤疮丙酸杆菌噬菌体内溶素的重组形式。该内溶素(endolysis)优选是从来自丙酸杆菌噬菌体29399B_C(GenBank:JX262225.1)的内溶素基因序列(基因ID:NC_018851;855个核苷酸碱基对长,284个氨基酸,蛋白质ID:97935.1)克隆的,其被密码子优化以用于在大肠杆菌中表达并克隆到可商购的pET303/CT-His表达载体中。
特别有用的内溶素的核苷酸序列是根据以下列出的序列ID SEQ ID1:
尤其优选的方面涉及如下内溶素,其中从基因的3'末端去除终止密码子以容纳6X组氨酸标签。
具有C末端组氨酸标签(x6)的内溶素的多肽序列
也可能任选包含在本发明的组合物中的内溶素的核酸分子包含能够特异性结合到痤疮丙酸杆菌的细胞和/或裂解痤疮丙酸杆菌的细胞的内溶素片段、变体和融合体。
本发明的组合物包含局部可接受的载体,所述局部可接受的载体可包括无水基质(anhydrous base)、凝胶、洗剂、乳膏或乳液。
本发明的组合物优选是洗去型组合物,并且这通过包含1-80重量%的表面活性剂来实现。通常,表面活性剂可选自在众所周知的教科书(如Schwartz&Perry的“SurfaceActive Agents”,第1卷,Schwartz,Perry&Berch的Interscience 1949,第2卷,Interscience 1958,和/或Manufacturing Confectioners Company出版的“McCutcheon’sEmulsifiers and Detergents”的现行版,或“Tenside-Taschenbuch”,H.Stache,第2版,Carl Hauser Verlag,1981)中描述的表面活性剂。可以使用任何类型的表面活性剂,即阴离子、阳离子、非离子、两性离子或两性表面活性剂。
特别优选的表面活性剂是皂。皂是用于本发明的组合物的个人洗涤应用的合适表面活性剂。皂优选为C8-C24皂,更优选为C10-C20皂,并且最优选为C12-C16皂。皂可具有或可不具有一个或多个碳碳双键或三键。皂的阳离子可为碱金属、碱土金属或铵。优选地,皂的阳离子选自钠、钾或铵。更优选地,皂的阳离子是钠或钾。
皂可通过将脂肪和/或脂肪酸皂化而获得。通常用于皂制造中的脂肪或油可为,例如,牛脂、牛脂三硬脂精(tallow stearines)、棕榈油、棕榈三硬脂精、豆油、鱼油、蓖麻油、米糠油、向日葵油、椰子油、巴巴苏油、棕榈仁油等。在以上方法中,脂肪酸衍生自选自椰子、米糠、花生、牛脂、棕榈、棕榈仁、棉籽、大豆、蓖麻的油/脂肪。
典型的脂肪酸共混物由5-30%的椰子脂肪酸和70-95%的除硬化米糠油之外的脂肪酸组成。也可以其他所需比例使用衍生自其他合适的油/脂肪如花生、大豆、牛脂、棕榈、棕榈仁等的脂肪酸。最优选的皂是月桂酸皂。当皂存在于本发明的固体形式中时,其存在量按组合物的重量计为30-90%,优选50-85%,更优选55-75%。当皂存在于组合物的液体形式中时,其存在量按组合物的重量计为0.5-20%,优选1-10%。
或者,表面活性剂是非离子表面活性剂如C8-C22,优选C8-C16脂肪醇乙氧基化物,其包含1至8个环氧乙烷,该表面活性剂优选选自伯烷基硫酸盐、仲烷基磺酸盐、烷基苯磺酸盐或乙氧基化烷基硫酸盐。组合物可进一步包含阴离子表面活性剂如烷基醚硫酸盐,优选具有1-3个环氧乙烷基团的来自天然或合成来源和/或磺酸的那些。特别优选的是月桂醚硫酸钠。烷基聚葡糖苷也可存在于组合物中,优选具有C6至C16碳链长度的那些。清洁应用的液体形式中的合适的表面活性剂浓度按组合物的重量计通常大于0.5%但小于10%,优选1-5%。在固体组合物中,按组合物的重量计,表面活性剂优选以5-40%,优选10-30%存在。取决于组合物的形式,按组合物的重量计,水可优选以10-90%存在。在固体组合物中,水可以10-30%存在,而在液体或半固体组合物中,水可以40-90%存在。
本发明的组合物尤其适用于洗去型方法,其中抗微生物活性物质与表面的接触时间低,即小于5分钟,优选小于2分钟,进一步更优选小于1分钟并且在许多情况下小于15秒的量级。
当根据本发明的组合物是免洗型组合物时,其优选包含芳香剂、表面活性剂、有机防晒剂、无机防晒剂、润肤剂、湿润剂、体质颜料和防腐剂中的一种或多种。
防晒剂包括阻止有害紫外光的那些材料。优选的防晒剂是对氨基苯甲酸(PABA)、肉桂酸酯和水杨酸酯的衍生物。例如,可以使用阿伏苯甲酮(1789)、甲氧基肉桂酸辛酯和2-羟基-4-甲氧基二苯甲酮(也称为氧苯酮)。甲氧基肉桂酸辛酯和2-羟基-4-甲氧基二苯甲酮分别以商标MCX和Benzophenone-3可商购。也可使用(一种亚苄基樟脑衍生物)和甲酚曲唑三硅氧烷(一种苯并三唑)。进一步的实例包括奥克立林、苯基苯并咪唑磺酸(也称为)、水杨酸乙基己酯、萘酸二乙基己酯、bimotrizinole(商标为S)和bisoctrizole(M)。无机防晒剂包括反射或散射太阳光线的氧化物如二氧化钛和氧化锌。存在于组合物中的防晒剂的量可以根据所需的免受紫外线辐射的防护程度而变化。优选地,组合物包含0.01-15重量%,更优选0.1-10重量%,并且最优选0.5-7.5重量%的防晒剂。
可以使用的芳香剂类型的说明性实例包括包含萜烯和萜烯衍生物的那些,如在Bauer,K.等人,Common Fragrance and Flavor Materials,VCH Publishers(1990)中描述的那些。进一步的实例包括月桂烯、二氢月桂烯醇、柠檬醛、万寿菊酮、顺式香叶酸、香茅酸、其混合物。
载体用作组合物成分的稀释剂或分散剂。载体可以是水基、无水的或乳液,其中通常优选油包水或水包油乳液。如果需要使用水,则水通常构成组合物的余量,最优选为组合物的40-80重量%。
除水外,可任选地包含有机溶剂作为载体,以辅助本发明的组合物中的任何其他载体。实例包括链烷醇如乙醇和异丙醇。
其他合适的有机溶剂包括酯油如肉豆蔻酸异丙酯、肉豆蔻酸鲸蜡酯、肉豆蔻酸2-辛基十二烷基酯、鳄梨油、杏仁油、橄榄油和新戊二醇二癸酸酯。通常,此类酯油有助于乳化组合物,并且通常使用有效量来产生稳定且最优选油包水乳液。
如果需要,润肤剂也可用作载体。优选诸如1-十六烷醇(即鲸蜡醇)的醇。其他润肤剂包括硅油和合成酯。适用的硅油包括含有3-9个,优选4-5个硅原子的环状或直链聚二甲基硅氧烷。用作润肤剂的非挥发性硅油包括聚烷基硅氧烷、聚烷基芳基硅氧烷和聚醚硅氧烷共聚物。有用的非挥发性聚烷基硅氧烷包括聚二甲基硅氧烷。也可使用硅酮弹性体。可任选使用的酯润肤剂为:
(i)具有10-20个碳原子的脂肪酸的链烯基或烷基酯。其实例包括新戊酸异花生醇酯、异壬酸异壬酯、肉豆蔻酸油醇酯、硬脂酸油醇酯和油酸油醇酯;
(ii)醚-酯,如乙氧基化脂肪醇的脂肪酸酯;
(iii)多元醇酯。乙二醇单脂肪酸酯和二脂肪酸酯、二甘醇单脂肪酸酯和二脂肪酸酯、聚乙二醇(200-6000)单脂肪酸酯和二脂肪酸酯、丙二醇单脂肪酸酯和二脂肪酸酯、聚丙二醇2000单油酸酯、聚丙二醇2000单硬脂酸酯、乙氧基化单硬脂酸丙二醇酯、甘油基单脂肪酸酯和二脂肪酸酯、聚丙三醇聚脂肪酸酯、乙氧基化单硬脂酸甘油酯、1,3-丁二醇单硬脂酸酯、1,3-丁二醇二硬脂酸酯、聚氧乙烯多元醇脂肪酸酯、脱水山梨糖醇脂肪酸酯,以及聚氧乙烯脱水山梨糖醇脂肪酸酯是令人满意的多元醇酯;
(iv)蜡酯,如蜂蜡、鲸蜡、硬脂酸硬脂基酯和山萮酸花生基酯;和
(v)甾醇酯,其中胆固醇脂肪酸酯为实例。
当存在时,润肤剂通常占组合物的0.1-50重量%,包括其中包含的所有范围。
也可以包含具有10-30个碳原子的脂肪酸作为载体。此类脂肪酸的实例包括壬酸、月桂酸、肉豆蔻酸、棕榈酸、硬脂酸、异硬脂酸、油酸、亚油酸、花生酸、山萮酸或芥酸及其混合物。
组合物中还可使用多元醇类型的湿润剂。湿润剂通常有助于提高润肤剂的有效性,减少皮肤表面的脱皮,刺激累积皮屑的去除并且改善皮肤感觉。典型的多元醇包括甘油、聚亚烷基二醇并且更优选亚烷基多元醇及它们的衍生物,包括丙二醇、二丙二醇、聚丙二醇、聚乙二醇及其衍生物、山梨醇、羟丙基山梨醇、己二醇、1,3-丁二醇、1,2,6-己三醇、乙氧基化丙三醇、丙氧基化丙三醇及其混合物。为了最佳结果,湿润剂优选为丙二醇或透明质酸钠。可使用的其他湿润剂包括羟乙基脲。按组合物的重量计,湿润剂的量可为0.2-25%,并且优选0.5-15%。
可通过使用凡士林或石蜡来改善保湿。增稠剂也可用作组合物中载体的一部分。典型的增稠剂包括交联丙烯酸酯(例如982)、疏水改性的丙烯酸酯(例如1382)、纤维素衍生物和天然树胶。有用的纤维素衍生物是羧甲基纤维素钠、羟丙基甲基纤维素、羟丙基纤维素、羟乙基纤维素、乙基纤维素和羟甲基纤维素。适用于本发明的天然树胶包括瓜尔胶、黄原胶、菌核胶、卡拉胶、果胶以及这些树胶的组合。按组合物的重量计,增稠剂的量可为0.001-5%,最佳为0.01-0.5%。
也可存在表面活性剂。当存在时,表面活性剂的总量为组合物的2-40重量%,并且优选为4-20重量%,最佳为5-12重量%。表面活性剂选自阴离子、非离子、阳离子和两性活性物质。特别优选的非离子表面活性剂是具有C10-20脂肪醇或酸疏水物的那些,每摩尔疏水物与2至100摩尔的环氧乙烷或环氧丙烷缩合;乙二醇的单脂肪酸酯和二脂肪酸酯;脂肪酸甘油单酯;脱水山梨糖醇、单C8-C20脂肪酸和双C8-C20脂肪酸;嵌段共聚物(环氧乙烷/环氧丙烷);和聚氧乙烯脱水山梨糖醇及其组合。烷基多糖苷和糖脂酰胺(例如甲基葡糖酰胺)也是合适的非离子表面活性剂。
优选的阴离子表面活性剂包括皂、烷基醚硫酸盐和磺酸盐、烷基硫酸盐和磺酸盐、烷基苯磺酸盐、烷基和二烷基磺基琥珀酸盐、C8-20酰基羟乙基磺酸盐、酰基谷氨酸盐、C8-20烷基醚磷酸盐及其组合。
各种其他成分也可用于组合物中。活性物质被定义为除润肤剂和除仅改善组合物的物理特性的成分以外的皮肤有益剂。尽管不限于该类别,但一般的实例包括体质颜料(如滑石和二氧化硅),以及α-羟基酸、β-羟基酸和锌盐。β-羟基酸包括水杨酸。氧化锌和吡硫鎓锌是有用的锌盐的实例。
需要保护组合物(尤其是含水的组合物)免受有害微生物影响。抗微生物化合物如三氯生和防腐剂可能变得必要。合适的防腐剂包括对羟基苯甲酸的烷基酯、乙内酰脲衍生物、丙酸盐和多种季铵化合物。特别优选的防腐剂是对羟基苯甲酸甲酯、对羟基苯甲酸丙酯、苯氧乙醇和苯甲醇。防腐剂为组合物的0.1-2重量%。
包装可以是贴片、瓶子、管、滚珠涂敷器、抛射剂驱动的气雾剂装置、挤压容器或有盖的罐子。
根据本发明的另一方面,提供控制或根除来自皮肤的痤疮丙酸杆菌的方法,其包括将第一方面的组合物施用于所需皮肤表面上的步骤。方法优选是非治疗的。方法对于减少或消除皮肤上的痤疮特别有用。
现在将在以下非限制性实施例的帮助下说明本发明。
实施例
与金黄色葡萄球菌和表皮葡萄球菌相比,本发明的SCU分离物对痤疮丙酸杆菌抑
制的作用
痤疮丙酸杆菌菌苔的制备
将痤疮丙酸杆菌ATCC 6919和ATCC 29399在CY琼脂上在厌氧条件下于37℃生长3天。将培养物环重悬于PBS(pH 7.0)中,并将光密度设定为0.8(108个细胞/ml)。将108个细胞/ml的100μl铺平在含有20ml的1%TSA的10cm培养皿上。
表皮葡萄球菌和金黄色葡萄球菌菌苔的制备:
将金黄色葡萄球菌6538和表皮葡萄球菌12228在胰蛋白酶大豆琼脂平板中生长过夜。次日早晨,在盐水(0.85%NaCl)中加入充满培养物的环,将OD设置为0.8(108个细胞/ml)。将100μl的上述细胞悬液铺平在含有20ml的1%TSA的10cm培养皿上。
头状葡萄球菌(SCU)细胞沉淀的点斑
在10ml TSB中使头状葡萄球菌解脲亚种(SCU)生长过夜。次日早晨,将培养物离心,用盐水洗涤,并重悬于1ml新鲜TSB中。将10μL重悬的培养物点斑到含有痤疮丙酸杆菌、金黄色葡萄球菌和表皮葡萄球菌菌苔的平板上。将平板在厌氧条件下于37℃孵育。SCU对痤疮丙酸杆菌、金黄色葡萄球菌和表皮葡萄球菌的作用在下表中总结为抑制区(ZOI):
经痤疮丙酸杆菌和硫酸铵处理的不含细胞的SCU上清液的共孵育研究
使痤疮丙酸杆菌ATCC 6919在厌氧条件下生长3天,然后将OD设为0.8(108个细胞/ml)。使用上述培养物进行连续稀释直至104个细胞/ml。将经SCU硫酸铵处理的不含细胞的培养物上清液用于该实验。将100μl稀释的106个痤疮丙酸杆菌ATCC 6919和100μl经硫酸铵处理的SCU不含细胞的培养物上清液在1.5ml离心管中于37℃共孵育15分钟。孵育15分钟后,将800μl新鲜的TSB加入细胞混合物中以立即停止/减慢反应(稀释作用),然后进行连续稀释并加到1%TSA板上,并且在37℃下厌氧孵育3天。同时建立仅涉及用100μl PBS缓冲液处理进行的相似痤疮丙酸杆菌稀释的对照。
在下表中以对数减少的方式总结SCU对痤疮丙酸杆菌的作用
上表中的数据表明,本发明的SCU分离物在其抗微生物活性方面对痤疮丙酸杆菌是非常特异性的,并且对金黄色葡萄球菌或表皮葡萄球菌无效。
丙酸杆菌噬菌体来源的重组内溶素与头状葡萄球菌解脲亚种(SCU)来源的蛋白分
离物的协同作用:
使痤疮丙酸杆菌6919菌株(ATCC,USA)在厌氧条件下在来自甘油原液的RCM琼脂上生长。在新鲜制备的RCM琼脂平板上划线培养来自甘油原液的培养物环,并在37℃厌氧孵育4-5天。孵育后,将培养物从平板中取出并重悬于盐水中,然后在4℃下以8000rpm离心6分钟。将获得的沉淀重悬在10mM HEPES缓冲液(pH 7.0)中。在HEPES缓冲液中制备0.5的OD600培养物。将1:10稀释的0.5OD调节的培养物用于接触杀死测定,相当于每毫升106个细胞。
测定以200μl总体积进行。将14μl纯化的内溶素(最终浓度100μg/ml)和50μl头状葡萄球菌解脲亚种#1(SCU)来源的蛋白质(最终浓度750μg/ml)用于测定。作为对照,将136μl的1:10稀释的0.6OD600调整的培养物与64μl的HEPES缓冲液混合,使体积为200μl。类似地,对于内溶素和SCU蛋白,将所需量的蛋白与痤疮丙酸杆菌培养物混合用于个体治疗和联合治疗。将混合物混合并在摇床培养箱中于37℃孵育15分钟。孵育后,通过D/E培养基中的1:10连续稀释,然后进行盐水稀释来中和样品。将100μl的每种稀释液加到新鲜的RCM琼脂平板上,使其干燥。将平板用石蜡膜密封,并在厌氧室中于37℃孵育4-5天。孵育后,对菌落计数并按log CFU/ml评估滴度。计算个体治疗和联合治疗相对于对照的相对对数减少,并且数据显示在下表中:
样品 | Log CFU/ml | 相对对数减少 |
对照 | 7.53 | - |
内溶素(100μg/ml) | 7.24 | 0.29 |
SCU(750μg/ml) | 4.95 | 2.58 |
内溶素+SCU | 3.98 | 3.55 |
上表中的数据显示对于15分钟的组合暴露,内溶素和SCU蛋白对痤疮丙酸杆菌的协同抗微生物活性。
Claims (11)
1.用于选择性抑制痤疮丙酸杆菌(P.acnes)细菌生长的抗微生物组合物,其包含:
(i)头状葡萄球菌解脲亚种(Staphylococcus capitis ureolyticus,SCU)分离物;和
(ii)局部可接受的载体。
2.根据权利要求1所述的组合物,其中所述SCU分离物是使用包括以下步骤的方法制备的:
(i)在35至37℃的温度下在液体培养基中摇动SCU;
(ii)分离不含细胞的上清液;
(iii)通过用硫酸铵沉淀来浓缩所述上清液;
(iv)用磷酸盐缓冲液和甘油重悬步骤(iii)的沉淀物
以制备所需SCU分离物。
3.根据前述权利要求中任一项所述的组合物,其另外包含痤疮丙酸杆菌噬菌体来源的内溶素和编码它们的核酸分子。
4.根据权利要求3所述的组合物,其中所述内溶素是痤疮丙酸杆菌噬菌体内溶素的重组形式。
5.根据权利要求3或4所述的组合物,其中所述内溶素是从来自丙酸杆菌(Propionibacterium)噬菌体29399B_C(GenBank:JX262225.1)的内溶素基因序列(基因ID:NC_018851;855个核苷酸碱基对长,284个氨基酸,蛋白质ID:97935.1)克隆的,其被密码子优化以用于在大肠杆菌(E.coli)中表达并克隆到可商购的pET303/CT-His表达载体中。
6.根据权利要求3至5中任一项所述的组合物,其中从所述基因的3'末端去除终止密码子以容纳6X组氨酸标签。
8.根据前述权利要求中任一项所述的组合物,其中所述核酸分子包含能够特异性结合到痤疮丙酸杆菌细胞和/或裂解痤疮丙酸杆菌细胞的内溶素片段、变体和融合体。
9.前述权利要求中任一项所述的组合物,其中所述局部可接受的载体包括无水碱、凝胶、洗剂、乳膏或乳液。
10.控制或根除来自皮肤的痤疮丙酸杆菌的方法,其包括将前述权利要求中任一项所述的组合物施用于所需皮肤表面上的步骤。
11.根据权利要求10所述的方法,其用于减少或消除皮肤上的痤疮。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18177459 | 2018-06-13 | ||
EP18177459.7 | 2018-06-13 | ||
PCT/EP2019/063765 WO2019238409A1 (en) | 2018-06-13 | 2019-05-28 | An antimicrobial composition for selectively inhibiting growth of p. acnes bacteria |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113166210A true CN113166210A (zh) | 2021-07-23 |
Family
ID=62630981
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201980034215.6A Pending CN113166210A (zh) | 2018-06-13 | 2019-05-28 | 用于选择性抑制痤疮丙酸杆菌生长的抗微生物组合物 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP3774855B1 (zh) |
CN (1) | CN113166210A (zh) |
MX (1) | MX2020012467A (zh) |
WO (1) | WO2019238409A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112771149A (zh) * | 2018-08-23 | 2021-05-07 | 韩国亿诺生物有限公司 | 新颖颗粒丙酸杆菌菌株及包含该菌株或其培养物的用于预防或治疗痤疮的组合物 |
CN116270368A (zh) * | 2023-05-15 | 2023-06-23 | 天津悟空美容科技有限责任公司 | 一种抗痤疮化妆品及制备方法 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2023516922A (ja) * | 2020-02-25 | 2023-04-21 | ユニリーバー・アイピー・ホールディングス・ベスローテン・ヴェンノーツハップ | プレバイオティックな有益性のための糖類とグリセロールの組み合わせの使用 |
EP4114352A1 (en) * | 2020-03-02 | 2023-01-11 | Unilever IP Holdings B.V. | An effective anti-acne personal care composition |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104284664A (zh) * | 2012-03-14 | 2015-01-14 | 斯克里普斯研究所 | 广谱抗生素Arylomycin类似物 |
US20160346294A1 (en) * | 2014-01-29 | 2016-12-01 | Vyome Biosciences Pvt. Ltd. | Treatments for resistant acne |
US20170157186A1 (en) * | 2015-12-02 | 2017-06-08 | Smart Phage, Inc. | Phage to treat bacteria on skin |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7572602B1 (en) * | 2004-12-03 | 2009-08-11 | The United States Of America As Represented By The Secretary Of Agriculture | Nucleic acid encoding endolysin fusion protein |
-
2019
- 2019-05-28 MX MX2020012467A patent/MX2020012467A/es unknown
- 2019-05-28 WO PCT/EP2019/063765 patent/WO2019238409A1/en active Search and Examination
- 2019-05-28 CN CN201980034215.6A patent/CN113166210A/zh active Pending
- 2019-05-28 EP EP19728908.5A patent/EP3774855B1/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104284664A (zh) * | 2012-03-14 | 2015-01-14 | 斯克里普斯研究所 | 广谱抗生素Arylomycin类似物 |
US20160346294A1 (en) * | 2014-01-29 | 2016-12-01 | Vyome Biosciences Pvt. Ltd. | Treatments for resistant acne |
US20170157186A1 (en) * | 2015-12-02 | 2017-06-08 | Smart Phage, Inc. | Phage to treat bacteria on skin |
Non-Patent Citations (3)
Title |
---|
EWA JONCZYK-MATYSIAK等: "Prospects of Phage Application in the Treatment of Acne Caused by Propionibacterium acnes", 《FRONTIERS IN MICROBIOLOGY》, vol. 8, pages 88 - 11 * |
TAMMY L. BANNERMAN等: "Staphylococcus capitis subsp. ureolyticus subsp. nov. from human skin", 《INTERNATIONAL JOURNAL OF SYSTEMATIC BACTERIOLOGY》, vol. 41, no. 1, pages 144 - 147, XP055493126, DOI: 10.1099/00207713-41-1-144 * |
周长林等: "《微生物学》", 31 August 2015, 中国医药科技出版社, pages: 295 - 296 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112771149A (zh) * | 2018-08-23 | 2021-05-07 | 韩国亿诺生物有限公司 | 新颖颗粒丙酸杆菌菌株及包含该菌株或其培养物的用于预防或治疗痤疮的组合物 |
CN116270368A (zh) * | 2023-05-15 | 2023-06-23 | 天津悟空美容科技有限责任公司 | 一种抗痤疮化妆品及制备方法 |
Also Published As
Publication number | Publication date |
---|---|
EP3774855B1 (en) | 2024-08-28 |
WO2019238409A1 (en) | 2019-12-19 |
EP3774855A1 (en) | 2021-02-17 |
MX2020012467A (es) | 2021-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3774855B1 (en) | An antimicrobial composition for selectively inhibiting growth of p. acnes bacteria | |
TWI686209B (zh) | 包含胚芽乳酸桿菌培養物的抗菌化粧品組成物 | |
AU2017202471B2 (en) | Peptide for use in the treatment of skin conditions | |
CA2602108C (en) | Skin treatment compositions | |
US20170224750A1 (en) | Lactobacillus plantarum cncm i-4026 preparations and skin health | |
US11633348B2 (en) | Cosmetic use of engineered postbiotics comprising bacteriocins and/or endolysins | |
EP3969113A1 (en) | Use of a sugar or sugar alcohol | |
CN115135298A (zh) | 糖和甘油的组合用于益生元益处的用途 | |
CN111320678B (zh) | 抗菌肽突变体及其应用 | |
CN112996532A (zh) | 一种选择性抑制痤疮丙酸杆菌细菌生长的抗微生物组合物 | |
EP3723714B1 (en) | Propanediol monoacetate mononitrate | |
EP4114352A1 (en) | An effective anti-acne personal care composition | |
JP7187740B2 (ja) | 新規の使用 | |
WO2022069379A1 (en) | A personal care composition comprising amino acids | |
CN114569506A (zh) | 一种天然活性焕颜袪痘凝胶组合物及其制备方法 | |
KR20210081489A (ko) | 레인을 포함하는 피부 상재균에 대한 항균용 조성물 | |
KR20200075980A (ko) | 항생제 내성을 갖는 클렙시엘라 속의 균을 용균하는 신규한 박테리오파지 | |
US20100048476A1 (en) | Novel use of bacteriocin derived from enterococcus faecalis sl-5 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20210907 Address after: Rotterdam Applicant after: Unilever Intellectual Property Holdings Ltd. Address before: Rotterdam Applicant before: Unilever Nederland B.V. |
|
TA01 | Transfer of patent application right |